by David Wallace updated July 10, 2025 This is no wonderful “epiphany moment” article, just a quick report on a real myeloproliferative neoplasm (MPN) symptom I experience from time to time. Many mornings, I make a healthy smoothie to get me up and rolling. This morning I grabbed the wrong ingredient and sprinkled it in […]
What Rare Disease Day Means to Me
by David Wallace Hi, my name is David, and I am a polycythemia vera (PV) warrior. PV is a rare blood cancer. To me, living with a rare disease is not just a medical journey; it’s a testament to resilience and the power of community. Rare Disease Day, for me, is more than just a […]
What is Blast Phase Myeloproliferative Neoplasm?
Abstract Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as “blast-phase MPN”, is the most feared disease complication, with incidence estimates of 1–4% for essential thrombocythemia, 3–7% for polycythemia vera, and 9–13% for primary myelofibrosis. Diagnosis of MPN-BP requires the presence of ≥20% circulating or bone marrow blasts; a lower level of excess blasts […]
MPN Patient Advocate: Strategies for Self-Advocacy and Better Health Outcomes
by David Wallace Living with myeloproliferative neoplasms (MPNs) can be challenging both physically and emotionally. MPNs are rare blood cancers that require continuous management and care. The three main types of MPNs are myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). As a patient, it is crucial to become your own advocate in order […]
Ojjaara, FDA Approved for Treatment of Myelofibrosis with Anemia
September 15, 2023 Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia Approval is for use in myelofibrosis patients with anemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease, and over 30% will discontinue […]
- 1
- 2
- 3
- …
- 35
- Next Page »
